Delhi: The Indian pharmaceutical market (IPM) continued its upward momentum in February 2025, registering a 7.5% monthly growth in value, according to the latest Pharma Trac MAT report. The industry also recorded a 1.5% increase in unit sales compared to January 2025, reflecting steady demand across key therapeutic segments. On a year-on-year basis, the market saw an 8.1% growth compared to February 2024.
Therapy-wise Performance: Cardiac and Gastro Segments Drive Monthly Growth
The cardiac therapy segment saw the highest monthly increase, growing 9.2% in value and 1.5% in units compared to January 2025. The gastrointestinal segment followed closely, reporting an 8.6% value growth and 4.2% unit growth, indicating rising demand for digestive health medications.
The anti-infectives segment saw a 5.1% value growth month-on-month, despite a 2.1% dip in unit sales. Meanwhile, anti-diabetics posted 7.8% growth in value and 2.4% growth in unit sales.
The respiratory segment, often influenced by seasonal factors, registered a 1.1% increase in value but faced a 4.6% decline in unit sales. Pain and analgesics recorded 7.9% value growth, though units sold fell slightly by 0.6%.
Corporate Performance: Sun Pharma Maintains Lead in Monthly Sales
Among pharmaceutical companies, Sun Pharma (including Ranbaxy) continued its dominance, reporting a 10.2% monthly growth in value, reaching Rs 18,455 crore in sales for February 2025. Abbott (including Novo Nordisk and Abbott Healthcare) recorded Rs 13,246 crore in monthly sales, reflecting a 6.8% growth.
Cipla, a leader in respiratory and chronic therapies, reported Rs 11,639 crore in sales for February 2025, showing a 6.9% increase over the previous month. Mankind Pharma and Bharat Serums, known for their presence in women’s health and fertility, posted Rs 12,611 crore in monthly sales, growing by 8.2%.
Other notable performers included Dr. Reddy’s Laboratories, which grew by 9.4% month-on-month, and Zydus Lifesciences, which saw an 8.0% increase in value sales.
Top-Selling Brands: Augmentin, Glycomet GP, and Mixtard Register Monthly Growth
Among the best-performing brands in February 2025, GlaxoSmithKline’s Augmentin led with Rs 817 crore in sales, reflecting a 5.2% increase over January 2025. USV’s Glycomet GP, a leading anti-diabetic brand, followed with Rs 800 crore in sales, registering a 3.5% monthly growth.
Abbott’s Mixtard, a widely used insulin brand, recorded Rs 776 crore in sales, while Alkem’s Pan grew 7.9% month-on-month, reaching Rs 759 crore in sales.
Growth Drivers: Pricing and New Launches Boost Sales
Price growth remained the primary factor driving monthly market expansion, contributing 5.1% to overall growth. New product launches accounted for 2.1% growth, while changes in volume had a limited impact, registering a 0.3% increase.
The February 2025 market value was 7.5% higher than January 2025, showcasing consistent demand. This follows a 6.3% monthly growth recorded in January, highlighting a positive trend in pharma sales.
